Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00560703 · ClinicalTrials.gov registry record · Phase 2
Treatment of Patients With Blepharitis and Facial Rosacea
A Phase 2 study of Dry Eye and Blepharitis, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
- 8
- Study locations
NCT00560703: Completed Phase 2 study of Dry Eye and Blepharitis, sponsored by Galderma R&D.
NCT00560703 is a Phase 2 study of Dry Eye and Blepharitis that has completed, run by Galderma R&D. The registered enrollment target is 70 participants, below the 94-participant average among 41 other Dry Eye trials with a reported enrollment target (26% lower). The trial reports 8 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00560703, a Phase 2 study of Dry Eye and Blepharitis, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
- 8
- Study locations
Study Summary
To determine the safety and efficacy of sub-antimicrobial dose COL-101 in the treatment of patients who have both blepharitis and facial rosacea
Primary Outcome
Bulbar conjunctival hyperemia will be assessed using an ordered categorical value ranging from 0 (Clear) to 4 (Severe). Hyperemia is graded on the following scale and half scores are acceptable: None (0) = normal Mild (1) = slight localized injection Moderate (2) = pink color Severe (3) = red color Very Severe (4) = marked dark redness
Conditions Studied
Interventions
- DRUG placebo
- DRUG COL-101 (doxycycline, USP) capsules
Study Locations (8)
Arkansas
- Pleasant Valley Ophthalmology - Little Rock
Florida
- Warren Scherer, MD - Naples
Kentucky
- Kentucky Lions Eye Center - Louisville
Missouri
- Washington University School of Medicine - St Louis
New York
- Marguerite McDonald, MD - Lynbrook
Oklahoma
- Dean McGee Eye Institute - Oklahoma City
Pennsylvania
- Anita Nevyas-Wallace, MD - Bala-Cynwyd
Utah
- Tanner Clinic - Layton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2007-11 |
| Est. Completion | 2009-07 |
| Phase | Phase 2 |
What the finished NCT00560703 record still lists
NCT00560703 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 94-participant average among 41 other Dry Eye trials with a reported enrollment target (26% lower).
The record links to 3 conditions, with Dry Eye appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00560703 lists 8 locations in 8 states (Arkansas, Florida, Kentucky).
Frequently Asked Questions
What is clinical trial NCT00560703 about?
NCT00560703 is a clinical study titled "Treatment of Patients With Blepharitis and Facial Rosacea". To determine the safety and efficacy of sub-antimicrobial dose COL-101 in the treatment of patients who have both blepharitis and facial rosacea
What is the current status of trial NCT00560703?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2007-11. Estimated completion is 2009-07.
What conditions does trial NCT00560703 study?
This clinical trial studies the following conditions: Dry Eye, Blepharitis, Meibomianitis.
What interventions are being tested in trial NCT00560703?
The interventions under investigation include: placebo (DRUG), COL-101 (doxycycline, USP) capsules (DRUG).
Who is sponsoring clinical trial NCT00560703?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00560703 being conducted?
This trial has 8 study locations across Arkansas, Florida, Kentucky, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Eye
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00560703's enrollment target sits among peer trials
70 14th of 41 higher than 28 of 41 other Dry Eye trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dry Eye trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye
RECRUITING · Phase 2
-
An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye
RECRUITING · Phase 2
-
Phase 2b Controlled Study of Dosing Techniques - Part B
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Assess the Safety and Efficacy of ECF843 vs Vehicle in Subjects With Dry Eye Disease
COMPLETED · Phase 2
-
An 8-week Study to Evaluate Safety and Efficacy of NGF Eye Drops Solution Versus Vehicle in Patients With Dry Eye
COMPLETED · Phase 2
-
Can Pregabalin Reduce the Frequency and Severity of Dry Eye Symptoms After Laser-assisted in Situ Keratomileusis?
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia